AstraZeneca sheds £15 billion of market cap as weight-loss-pill data underwhelms investors
AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...
AstraZeneca's Obesity Pills Revealed Positive Result In Phase I Trials
In its presentation at ObesityWeek 2024 meeting in Texas, the multinational drug company AstraZeneca (NASDAQ:AZN) revealed ...
The Pharma Letter10h
AstraZeneca sees progress in obesity drug trials, highlights new oral option
AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...
emjreviews.com12h
AZ’s new obesity pill shows promise, enters phase II
AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.
AstraZeneca’s Promising Obesity Treatment Advances Justify Buy Rating: Analyst Report
Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on AstraZeneca (AZN – Research Report) and keeping the price ...
Vistagen to Present at the 2024 Neuroscience Education Institute Congress
Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that it will present posters highlighting new ...
BioSpace15h
AstraZeneca Bolsters Obesity Pipeline With Promising Early Data for Candidates
While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...
Obesity Pill Data Portend Competition, Hitting Drugmaker Shares
Obesity pill data released by Viking Therapeutics Inc. and AstraZeneca Plc at a big conference foreshadowed an increasingly competitive landscape for weight-loss therapies, sending down shares of ...